Physician profile
John Kobert
NPI 1376528810
$8,275.91
in general payments reported to CMS, 2019-2025
20 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $5,926 · 2021: $284 · 2022: $326 · 2023: $454 · 2024: $580 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446 · Education: $30.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,445.91 |
| Education | $30.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,333.86 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $361.76 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $229.95 | 2021-2025 | Rayaldee |
| Vifor Pharma, INC. | $213.05 | 2019-2023 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $158.55 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $144.11 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $123.70 | 2022-2023 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.46 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $106.41 | 2023-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $104.14 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $68.67 | 2024 | Purified Cortrophin Gel |
| Amgen INC. | $67.55 | 2021-2022 | |
| Horizon Therapeutics Plc | $63.48 | 2019-2022 | |
| Glaxosmithkline, LLC. | $52.79 | 2022-2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $31.63 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $23.98 | 2025 | Vafseo |
| Kyowa Kirin, INC. | $21.59 | 2023 | |
| Lilly USA, LLC | $20.77 | 2025 | Jardiance |
| Cormedix INC. | $17.35 | 2024 | Defencath |
| Ultragenyx Pharmaceutical INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kobert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.